CAQK, a peptide associating with extracellular matrix components targets sites of demyelinating injuries

Charly Abi-Ghanem, Deepa Jonnalagadda, Jerold Chun, Yasuyuki Kihara and Barbara Ranscht*
Center for Genetic Disorders and Aging, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States

The destruction of the myelin sheath that encircles axons leads to impairments of nerve conduction and neuronal dysfunctions. A major demyelinating disorder is multiple sclerosis (MS), a progressively disabling disease in which immune cells attack the myelin. To date, there are no therapies to target selectively myelin lesions, repair the myelin or stop MS progression. Small peptides recognizing epitopes selectively exposed at sites of injury show promise for targeting therapeutics in various pathologies. Here we show the selective homing of the four amino acid peptide, cysteine-alanine-lysine glutamine (CAQK), to sites of demyelinating injuries in three different mouse models. Homing was assessed by administering fluorescein amine (FAM)-labeled peptides into the bloodstream of mice and analyzing sites of demyelination in comparison with healthy brain or spinal cord tissue. FAM-CAQK selectively targeted demyelinating areas in all three models and was absent from healthy tissue. At lesion sites, the peptide was primarily associated with the fibrous extracellular matrix (ECM) deposited in interstitial spaces proximal to reactive astrocytes. Association of FAM-CAQK was detected with tenascin-C although tenascin depositions made up only a minor portion of the examined lesion sites. In mice on a 6-week cuprizone diet, FAM-CAQK peptide crossed the nearly intact blood-brain barrier and homed to demyelinating fiber tracts. These results demonstrate the selective

Abbreviations: BBB, blood-brain barrier; BSA, bovine serum albumin; CAQK, cysteine-alanine-glutamine-lysine; CFA, complete Freund’s adjuvant; CNS, central nervous system; CSPG, chondroitin sulfate proteoglycan; DAPI, 4,6-diamidino-2-phenylindole; EAE, experimental autoimmune encephalomyelitis; ECM, extracellular matrix; FAM, fluoresceinamine; FITC, fluorescein isothiocyanate; GFAP, glial fibrillary acidic protein; Hapln, proteoglycan link protein; Iba1, ionized calcium binding adaptor molecule 1; i.p., intraperitoneally; LPC, lysophosphatidylcholine (lyssolecithin); MBP, myelin basic protein; MRI, magnetic resonance imaging; MS, multiple sclerosis; NF-κB, nuclear factor kappa B; OCT, optimal cutting temperature compound; OPC, oligodendrocyte progenitor cell; PBS, phosphate-buffered saline; PET, positron emission tomography; PFA, paraformaldehyde; PID, post induction day; PTX, pertussis toxin; TBI, traumatic brain injury; TBST, Tris-buffered saline with 0.02% Triton X100, TNF, tumor necrosis factor; USPIO, ultrasmall super paramagnetic iron oxide nanoparticles.
targeting of CAQK to demyelinating injuries under multiple conditions and confirm the previously reported association with the ECM. This work sets the stage for further developing CAQK peptide targeting for diagnostic and therapeutic applications aimed at localized myelin repair.

**KEYWORDS**

peptide targeting, extracellular matrix, mouse demyelination models, tenascins, myelin repair

# Introduction

Myelin, a multilayered, lipid-rich membrane sheath formed by oligodendrocytes in the central nervous system (CNS), enables rapid nerve impulse conduction and sustains the functional integrity of neurons and their encircled axons. In multiple neurodegenerative diseases, compromised myelin and impaired nerve functions are closely interlinked. In multiple sclerosis (MS), peripherally activated T-cells and macrophages break through the blood-brain barrier and infiltrate the brain parenchyma causing local inflammation (Mapunda et al., 2022), thus activating a host of tissue reactions that proceed to destroying the myelin. Myelin injury and death of oligodendrocytes impair nerve functions and lead to neurodegeneration with progressive patient disability. Although current MS therapies are efficient in altering or suppressing the immune response, there are no treatments to repair damaged myelin and thus protect nerve functions. Oligodendrocyte progenitor cells (OPC) residing near MS lesion sites retain a limited myelin repair capacity during the early stages of the disease, however, they lose this vital ability with disease progression (Franklin and Goldman, 2015). The cause for remyelination failure is multi-factorial and includes lesion-associated factors that impinge on OPC proliferation, inhibit progenitor migration into lesion sites, or halt OPC maturation, and myelin formation (Galloway et al., 2020). Innovative approaches are needed to identify novel therapies that enable OPC-mediated regeneration of myelin during disease advancement or increase the resilience of myelin to damage.

Significant progress has been made in vitro and in animal models in identifying molecules and mechanisms that promote or inhibit remyelination (Franklin, 2002; Franklin and Ffrench-Constant, 2017). Amongst the latter, extracellular matrix (ECM) components are dynamically remodeled during injury and their interactions with surrounding cells exposing new epitopes or receptors induce injury-related pathological pathways (Zimmermann and Dours-Zimmermann, 2008; de Jong et al., 2020; Srivastava et al., 2020; Su et al., 2021). Upregulation of ECM components, including chondroitin sulfate proteoglycans (CSPGs), tenascins, and fragmented hyaluronan, block steps in OPC differentiation and myelination and are implicated in contributing to remyelination failure (Czopka et al., 2010; Karus et al., 2016; Srivastava et al., 2020; Su et al., 2021). Accordingly, studies in mouse models show that CSPG synthesis block or pharmacologically induced clearance promotes remyelination (Lau et al., 2012; Karus et al., 2016; Keough et al., 2016). Interventions with inhibitory tenasin-C deposition reduce susceptibility to inflammatory demyelinating experimental autoimmune encephalomyelitis (EAE) and improve remyelination in mice (Momcilovic et al., 2017; Bauch and Faisser, 2022). Thus, approaches to hinder the deposition of pathological ECM components or to neutralize its adverse effects have gained interest in approaching myelin repair.

With better molecular understanding of myelin destruction and repair processes, the next critical step is translating these findings into remyelination therapies. This entails the development of therapeutics effective in stimulating the remyelination processes and concentrating them at effective doses at sites of myelin damage. Systemic administration often requires high therapeutic concentrations that can lead to undesired side effects in patients. A further challenge is drug delivery across the blood-brain barrier (BBB) that limits access to the CNS (Daneman and Prat, 2015). A promising approach to overcome these limitations is the use of small peptides that target epitopes selectively exposed at myelin injuries. Differentially expressed molecules at lesion sites can serve as docking sites for concentrating drug conjugates or cargo-loaded nanoparticles, and thus increase the efficacy of targeted therapeutics while limiting side effects (Ruoslahi et al., 2010). Peptide targeting is emerging as a promising therapy for a variety of diseases (reviewed in Wang et al., 2022). In cancer, peptides deliver agents to unfold local actions that change signaling pathways or serve as agonists or antagonists for cancer-related receptors (Olson et al., 2009; Thundimadathil, 2012; Marquis et al., 2017; Ruoslahi, 2017; Scodeller and Asciiuto, 2020). Small peptides are often able to cross the blood-brain barrier raising a potential additional advantage for CNS targeting (Islam et al., 2021).

Aiming to identify peptides for targeting traumatic brain injuries (TBI), Ruoslahi and colleagues conducted a systemic in vivo peptide phage display library screen that identified a novel four amino acid peptide, cysteine-alanine-glutamine-lysine, referred to as CAQK (Mann et al., 2016).
This peptide selectively associates with focal and impact-induced brain lesions while not interacting with healthy brain and other tissues (Mann et al., 2016). Traumatic brain injury (TBI) lesions feature a myriad of cellular alterations, including the breakdown of the BBB, immune cell infiltration, activation of astrocytes and microglia, axon- and neuron degeneration, extracellular matrix remodeling, demyelination and oligodendrocyte death (George and Geller, 2018; Qin et al., 2021). Many of these key cellular pathologies in TBI are manifest in MS and other diseases associated with myelin destruction (Su et al., 2021). We thus speculated that CAQK peptide may also target sites of demyelination and potentially prove useful in advancing therapies aimed at achieving myelin repair. We here examined the homing of CAQK tetrapeptide to sites of myelin damage in mouse models of acute, immune-mediated, and toxic demyelination. We report selective targeting of CAQK to injured but not intact myelin in the three demyelination models and thus open prospects for exploring the potential utility of CAQK towards myelin repair.

Materials and methods

Materials

Peptides were synthesized with an N-terminal fluorescein amine (FAM) tag and provided at >90% purity by (Genscript). Lyophilized aliquots of ∼3–4 mg were stored at −80°C and reconstituted with sterile phosphate-buffered saline (PBS) for use in mice. Lysolecithin was from Sigma (Cat# L4129) and cuprizone from Thermo Fisher Scientific (Cat# 370-81-0).

Mice and mouse models of demyelination

All animal procedures were conducted in accordance with Institute Animal Care and Use Committee guidelines at Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA). The C57BL/6J mouse strain was used in all experiments. Mice constitutively expressing the red fluorescent tdTomato reporter in oligodendrocytes (in text CNP1-TdTom mice) were generated by crossing CNP1-Cre transgenic mice (Lappe-Siefke et al., 2003) with the Rosa26-tdTomato reporter (Jax # 007909) and used in some experiments.

Lysolecithin-induced focal demyelination

Focal demyelination was induced by stereotaxic injection of 1 µl of 1% lysolecithin solution into the right ventral white matter of 8–10-week-old male mouse spinal cords under ketamine/xylazine anesthesia (Arnett et al., 2004; Bielecki et al., 2016). Injections were made after piercing the dura mater with an 18G needle into the space between T12 and T13 and inserting a fine-tipped glass capillary connected to a Hamilton syringe mounted on an infusion pump run at a rate of 0.2 µl per minute over 5 min. The capillary was kept in place for at least 2 min to allow the solution to diffuse before retraction of the capillary and incision closure. Sham-operated mice were injected with vehicle (PBS). Animals were allowed to recover from surgery and were used for experimentation 24 h and 5 days after LPC injection.

Experimental autoimmune encephalomyelitis (EAE)

Robust EAE was reproducibly established in 8–12-week-old female mice by immunizing groups of 10 or 20 animals with 200 µg MOG35–55 peptide in combination with 200 mg Mycobacterium tuberculosis emulsified in complete Freund's adjuvant (CFA; EAE kit 2110; Hooke Laboratories, Lawrence, MA, United States) according to the manufacturer's protocol. Pertussis toxin (PTX; 80 ng in PBS) was administered intraperitoneally (i.p.) at the time of induction 0 and 24-h later. Mice in the control group were injected with PTX only. Females from the control and the experimental group were housed together in a cage. Starting at post-induction day 5 (PIDS) and ending on PID 28, mice were scored daily for clinical symptoms on the established rating scale (Kihara et al., 2005; Jonnalagadda et al., 2021). Mice were weighed and scored daily for signs of progressive paralysis: 0—no abnormalities; 0.5—mild loss of tail tone; 1.0—complete loss of tail tone; 1.5—mildly abnormal gait and difficulty in righting; 2.0—abnormal gait and hindlimb weakness; 2.5—beginning hindlimb paralysis; 3.0—complete or almost complete hindlimb paralysis; 3.5—paralysis and inability to upright body; 4.0—hindlimb paralysis and forelimb weakness or paralysis; 4.5—paralysis without an attempt to move around the cage; 5.0—moribund or dead. The scoring was performed blinded to the experimenter.

Demyelination with cuprizone

C57BL/6J 8-week-old male mice were maintained for 6 weeks on a ground chow without or supplemented with 0.2% cuprizone (Bis (cyclohexanone) oxalidihydrazone 98%; Thermo Fisher Scientific, Cat# 370-81-0). Mice were weighed every other day and the cuprizone-fed group showed lower body weights compared to control mice on a normal chow consistent with the effectiveness of the supplement (Tagge et al., 2016).
Peptides

In all experiments, FAM-CAQK or FAM-control scrambled (FAM-ACKQ) peptides were administered at 100 nmoles/100 µl in PBS into the tail vein or the plexus retroorbitalis. After 60 min in the circulation, animals were anesthetized by inhalation of isofluorane (VetOne, Cat#502017). Circulating FAM-peptides were removed from the bloodstream by perfusion with PBS. Spinal cords were isolated and drop fixed in 4% paraformaldehyde (PFA; Sigma Aldrich, Cat#P6148) in PBS overnight. For harvesting brain cortices, animals were perfused with 4% PFA in PBS. Tissue was postfixed overnight at 4°C in 4% PFA. All tissues were cryoprotected by immersion into 30% sucrose solution 48 h before freezing and then embedded in optimal cutting temperature (OCT) compound (Scigen Cat#4586) on dry ice/isopentane/methyl pentane at −78°C. Tissues were kept frozen at −20°C until use.

Processing and immunohistochemistry of spinal cord tissue

Spinal cords from LPC injured or sham-operated mice were cut in cross-section at the level of the injury site. Spinal tissue from mice with EAE or controls was partitioned into four pieces and embedded en block for simultaneous cutting at different levels. Crosssections were cut on a cryostat at 12 µm and collected on Fisherbrand™ Superfrost™ Plus microscope slides (Fisher Scientific Cat#12-550-15). Staining was performed essentially as previously described (Colakoglu et al., 2014). Unspecific binding sites were blocked by sequential incubation with 1% glycine and blocking solution (5% BSA, 2% normal donkey serum, 0.02% Triton X100) for 15 min and 1 h, respectively. Primary antibodies diluted in blocking solution were applied overnight at 4°C in a humid chamber. Slides were washed three times with PBS before being incubated with species-specific secondary antibodies coupled to either Alexa-488, Alexa-594, or Alexa-647 in Tris-buffered saline with 0.02% Triton X100 (TBST) for 1 h at room temperature. After three washes in PBS, slides were counterstained with blue-fluorescent nuclear DNA stain (DAPI) and mounted using Fluoromount G. Staining was examined on a Zeiss LSM 710 confocal microscope. The following primary antibody reagents were used: Rabbit anti-fluorescein/Oregon Green (Thermo Fisher Scientific, Cat#A-889, RRID:AB_221561), goat anti-FITC (Thermo Fisher Scientific, Cat# PA1-26793, RRID:AB_794297), rat anti-MBP aa 82-87 (Millipore, Cat# MAB386, RRID:AB_94975), rabbit anti-Olig2 (Millipore, Cat# AB9610, RRID:AB_570666), mouse mAb anti-CC1 (Millipore Cat# OP80, RRID:AB_2057371), rat anti-GFAP monoclonal antibody 2.2B10 (Thermo Fisher Scientific Cat# 13-0300, RRID:AB_2532994), rabbit anti-Iba1 (Wako Cat#019-19741, RRID:AB_839504), rat anti-tenascin-C (R&D Systems, Cat# MAB2138, RRID:AB_2203818), and goat anti-tenascin-R (R&D Systems, Cat# AF3865, RRID:AB_2207009). Cross absorbed secondary antibodies were from Thermo Fisher Scientific: donkey anti-rabbit Alexa 488 (Cat# A21206, RRID:AB_2535792); donkey anti-goat Alexa 488 (Cat# A32814TR; RRID: AB_2866497); donkey anti-rat Alexa 594 (Cat# A-21209; RRID:AB_2535795); goat anti-rabbit Alexa 594 (Cat# A11037; RRID:AB_2534095); goat anti-mouse Alexa 594 (Cat# A11005; RRID:AB_2534073); goat anti-rat Alexa 647 (Cat# A-21247, RRID:AB_141778); donkey anti-rabbit Alexa 647 (Cat# A-31573, RRID:AB_2536183); goat anti-mouse Alexa 647 (Cat# A-21235, RRID:AB_2535804). Negative signals in controls without primary antibodies and the use of primary antibodies of inappropriate species established specificity of the secondary antibodies.

Staining of brain tissue

Coronal sections (30 µm; Leica cryostat CM3050S) were cut in anterior to posterior direction starting at the level of bregma -1.58 mm. To estimate the status of myelination, brain sections were mounted onto gelatin-coated slides for staining with Black Gold II (Biosensis, Thebarton, SA, Australia; Cat #TR-100-BG). Free floating immunofluorescence staining was performed to detect different neural cell types and extracellular matrix proteins. Briefly, after washing the brain sections in PBS, the FAM signal was amplified with an anti-FITC polyclonal antibody (Thermo Fisher Scientific, Cat# PA1-26793, RRID:AB_794297) or fluorescein/Oregon green polyclonal antibody (Thermo Fisher Scientific, Cat# A-889; RRID:AB_221561). Primary antibodies used were chicken anti-GFAP (Neuromics, Cat#CH22102, RRID:AB_10014322), rabbit anti-MBP (Abscam, Cat# ab-40390, RRID:AB_1141521), rabbit anti-Iba1 (Wako, Cat# 019-19741, RRID:AB_839504), rabbit anti-tenascin R (R&D Systems, Cat# AF3865, RRID:AB_2207009), and rat anti-tenascin C (R&D systems, Cat# MAB2138, RRID:AB_2203818) in 5% normal donkey serum (Jackson Immuno Research Cat# 017-000-121) at room temperature overnight. The tissue was washed thrice in PBS the next day for 5 min each and incubated with the corresponding secondary antibody (goat anti-chicken Alexa Fluor 568, Thermo Fisher Scientific, Cat#A-11041, RRID:AB_2534098; donkey anti-rabbit Alexa Fluor 568 Invitrogen, Cat#A-10042, RRID:AB_2534017; goat anti-rat IgM Alexa Fluor 647, Thermo Fisher Scientific, Cat# A21248, RRID:AB_2535861; donkey anti-goat Alexa Fluor 647, Thermo Fisher Scientific, Cat# A21447, RRID:AB_2535864) in 0.3% TritonX-100/PBS for 1.5 h at room temperature in the dark. Care was taken to minimize exposure to light from this step onward. After washing thrice in PBS, the sections were mounted onto gelatin-coated slides and coverslipped with a mounting medium containing DAPI (Vectashield, Cat#H-1500).
Imaging

Sections with fluorescent labels were imaged on the Zeiss LSM 710 NLO Multiphoton microscope. Histological brain sections were analyzed using a Keyence microscope (BZ-X-800 series). ImageJ version 1.52q \(^1\) was used for image processing.

Data reproducibility

For each time point and condition, 3–5 animals were used, and from each animal 2–4 sections were examined to obtain results.

Results

Mouse models of demyelination

To probe the ability of CAQK peptide to associate with sites of demyelination injury, we employed multiple mouse models that reflect different aspects of acute and chronic demyelination (Denic et al., 2011; Ransohoff, 2012). Rapid focal demyelination with immune cell infiltration and a compromised blood-brain barrier was induced by a local lysophosphatidylcholine (LPC; lysolecithin) injection into the spinal cord. In this model, acute spatiotemporally precise damages to the lipid-rich myelin membrane sheaths are observed at the injection site as early as 24 h with continuing demyelination for up to 7 days after injury (Hall, 1972; El Waly et al., 2014). In the toxin-induced cuprizone model, demyelination occurs in mice fed the cuprizone diet with a highly reproducible time course and well-defined mechanisms in the corpus callosum and more variable results in other fiber tracts (Skripuletz et al., 2011; Praet et al., 2014). Cuprizone is a copper chelator that induces mitochondrial toxicity and death of oligodendrocytes. After 6-weeks on the cuprizone diet, mice show strain-dependent demyelination that reflects different aspects of acute and chronic demyelination (Constantinescu et al., 2011; Hasselmann et al., 2017). Here, peripheral administration of myelin protein peptides results in the activation of peripheral T-cells that transgress the blood-brain barrier where they induce inflammatory myelin damage accompanied by neurodegeneration and gliosis with simultaneous counteracting anti-inflammatory processes and remyelination. EAE mice develop ascending paralysis after EAE induction with the most severe clinical manifestations in the spinal cord permitting the monitoring of disease severity. Utilizing these models allowed us to assess CAQK peptide association in the demyelinated brain and spinal cord under different pathophysiological conditions.

CAQK peptide homes to sites of focal demyelination inflicted by acute lysolecithin injection

Acute focal demyelination induced by stereotactic injection of lysolecithin results in a defined injury site with an open blood-brain barrier like in the TBI model plus has high selective toxicity to oligodendrocytes and myelin while leaving neurons and axons largely intact (Blakemore and Franklin, 2008). Demyelination is detectable within 24 h and reaches a maximum by 7 days post LPC injection after which remyelination occurs (El Waly et al., 2014). We employed this rapid model to test the hypothesis that CAQK peptide homes to injured myelin. A unilateral injection of 1% lysolecithin was made into the ventral funiculus of the mouse spinal cord to induce the lesion. FAM-CAQK was administered intravenously at a concentration of 100 nmoles/100 µl at 24 h or 5 days post-injury and allowed to circulate for 1 h before perfusion and tissue harvesting. Sites of demyelinating injury correlate with the accumulation of DAPI+ stained mononuclear cells (Luo et al., 2014; Bielecki et al., 2016; Lozinski et al., 2021). We utilized this characteristic to localize the lesion area and detect the FAM-CAQK label in the ventral spinal cord white matter near the injection site. As illustrated for the 5-day post lesion time point, we observed the accumulation of FAM-CAQK peptide at the injury site identified by an increased density of mononucleated DAPI+ cells and fragmented myelin stained for myelin basic protein (MBP; Figures 1A–D). The peptide was not detected in the spinal cords of control sham-operated (PBS injected) mice showing regular densities of DAPI+ cells (Figures 1E–H), and secondary antibody controls at a DAPI-dense lesion site showed no signals (Figures 1I–L). Similar results were obtained for the 24 h post lesion time point (not shown). These observations supported the ability of CAQK to home to lesion sites in an established mouse demyelination model and encouraged further studies in long-term mouse models of demyelination.

CAQK homes to the demyelinated corpus callosum in the cuprizone model

To attain further evidence for the targeting of CAQK peptides to sites of demyelinating injury, we employed additional mouse models of established demyelination. First, since acute LPC-induced demyelination is induced by inflicting an open wound that disrupts the blood-brain barrier and leads to immune cell accumulation, we sought to investigate CAQK
targeting in a model of demyelination that is independent of peripheral immune cell invasion. Feeding mice a diet containing the neurotoxin cuprizone leads to myelin loss in central white matter tracks (Praet et al., 2014). Demyelination extends to multiple brain areas, including the cortex and hippocampus, and is well-defined and highly reproducible in the corpus callosum in the C57BL6 mouse strain (Skripuletz et al., 2008; Schmidt et al., 2013). Although early alterations of the BBB have been noted (Skripuletz et al., 2011; Berghoff et al., 2017), the blood-brain barrier is intact in C57BL/6 mice on the cuprizone diet for 6 weeks allowing studies of demyelination in the absence of a peripheral immune response. Thus, to characterize CAQK peptide targeting under non-inflammatory conditions and an intact (or minimally altered) BBB, we fed 8-week-old mice a 0.2% cuprizone diet for 6 weeks (Praet et al., 2014), and then assessed homing of FAM-CAQK peptide to demyelinating fiber tracts of the corpus callosum.

The cuprizone diet produced pronounced demyelination, most evident by the reduction in Black Gold II staining in the corpus callosum (Figure 2A). For comparison, the full extent of myelination is shown in naïve mice fed a normal diet (Figure 2D). Consistent with the reported loss of myelin from several brain areas in mice on the 6-week cuprizone diet, FAM-CAQK peptide was detected in cortical and hippocampal areas and the corpus callosum (Figures 2B,C). In contrast, the peptide did not associate with normal healthy myelin in the brains of naïve mice (Figures 2E,F).

To determine if CAQK associates with specific structures within the demyelinated corpus callosum, brain sections from peptide-treated mice fed the cuprizone diet were stained.
CAQK peptide targets areas of demyelination in the cuprizone model. Histological Black Gold II staining detects myelin in coronal brain sections of (A) FAM-CAQK peptide-treated cuprizone treated mice and (D) naïve mice. Demyelination is indicated by the reduction of Black Gold II labeled myelin in multiple brain areas (A) in mice on the cuprizone diet compared to (D) control mice on a normal diet. Note in particular the reduced black myelin signal in the corpus callosum in (A) (yellow arrowhead) compared to (D); images at 10× magnification. (B) FAM-CAQK peptide (green) targets the demyelinated areas including the cortex (Ctx) in cuprizone-treated mice, and in (E) is absent from myelin in the naïve brain; images at 20× magnification with identical exposure time. In both conditions, circulating peptide associates with the choroid plexus (white arrows in B,E) that separates the blood from cerebral spinal fluid. The framed regions with the centered corpus callosum (yellow arrow) are shown enlarged in (C,F), correspondingly. Ependymal cells facing the cerebral spinal fluid (small arrows in C) harbor the peptide. DAPI staining (blue) demarcates cellular nuclei in (B,C,E,F). Scale Bar = 500 µm.

for cell type and myelin specific markers, including glial fibrillary protein (GFAP) for astrocytes (Figure 3B), MBP for myelin (Figure 3E) and ionized calcium binding adaptor molecule 1 (Iba1) for resident microglia (Figure 3H). Images taken from the medial corpus callosum show FAM-CAQK peptide staining (Figures 3A,D,G) on fibrous extracellular material associated with GFAP+ reactive astrocytes that are highly upregulated in this area (Figures 3B,C). FAM-CAQK signal also extended beyond this region to include cells with intermediate to low GFAP expression around fibers of the fornix and the dorsal hippocampal commissure (Figure 3C). Consistent with published work analyzing myelin after 6 weeks on the cuprizone diet, myelin was largely lost as indicated by a modest staining signal for MBP (Figures 3E,I; see Praet et al., 2014). Little if any of the FAM-CAQK signal overlapped with the MBP+ staining. Iba1+ microglia (Figure 3H) that are sparse at the 6-week cuprizone feeding timepoint (Praet et al., 2014)
FIGURE 3
FAM-CAQK peptide associates with reactive astrocytes in corpus callosum during cuprizone-mediated demyelination. FAM-CAQK peptide is targeted to the demyelinating crossing fiber tracts in the corpus callosum (hatched lines) in mice after 6 weeks on the cuprizone diet (A,D,G, green). Peptide association (in C) is prominent with GFAP+ reactive astrocytes (B, magenta). Staining for MBP+ myelin (E, magenta) and microglial Iba1 (H, magenta) is marginal at the 6-week feeding point and no association of FAM-CAQK is evident; merged images (C,F,I) respectively. D, dorsal; V, ventral; L, lateral; M, medial. Scale bar = 50 µm.

also did not show FAM-CAQK peptide association. For controls, mice fed a normal diet did not accumulate FAM-CAQK peptide in the normal myelinated corpus callosum (Supplementary Figure S1).

Finally, as FAM-CAQK was reported to associate with extracellular matrix components in a mouse model of traumatic brain injury (Mann et al., 2016), we tested its association with extracellular matrix proteins in the cuprizone model. Tenascin-C and tenascin-R, components of the ECM produced at CNS injury sites mainly by reactive astrocytes are dynamically remodeled during demyelinating injury (Zhao et al., 2009) and were chosen for analysis. Examination of FAM-CAQK
CAQK associates in proximity of cells located at lesion sites in the EAE model

As CAQK is associated with demyelinating lesions in an amorphous pattern, we next queried by double labeling whether the peptide targets specific cell types. Spinal cord sections from EAE mice treated at disease onset (score 1) with FAM-CAQK peptide were used for analyses. Peptide association with oligodendrocytes was assessed in mice expressing the fluorescent tdTomato reporter in transgenic CNP1-Cre mice (Zhao et al., 2009). In contrast to observations in the TBI model (Mann et al., 2016), oligodendrocytes showed no or only a rare association with CAQK peptide (Figures 6A–C). However, we detected CAQK in association with reactive astrocytes and cells that make up the immune response. Examination of spinal cord sections revealed a gross overlap of FAM-CAQK with GPAP+ reactive astrocytes at lesion sites at the tissue rim (Figures 6D–F). Staining for microglial cells labeled with anti-Iba1 antibody (Figures 6G–I) or for CD3+ immune cells (Figures 6J–L) similarly showed partial overlap with the FAM-CAQK peptide signal. These results suggest that in the inflammatory demyelination EAE model, FAM-CAQK peptide targets lesions and localizes in proximity to infiltrating immune cells, microglia, and reactive astrocytes.

CAQK associates with tenascins in EAE demyelinating lesions

Reactive astrocytes contribute to changing the extracellular milieu at CNS injury sites (Roll and Faissner, 2019). The ECM molecule tenasin-C is absent in the healthy adult CNS but upregulated and deposited by reactive astrocytes at CNS injury sites (Roll and Faissner, 2019). Tenasin-C, expressed by astrocytes and oligodendrocytes in the adult CNS also undergoes extensive remodulation during CNS injury (Zhao et al., 2009). As CAQK was reported to bind components of an ECM complex, including tenasin-R, in the TBI model (Mann et al., 2016) and we consistently observed extracellular fibrous structures harboring the peptide, we next investigated FAM-CAQK association in combination with tenascins. First, staining for MBP showed in the EAE model that FAM-CAQK associates only marginally, if at all, with myelin membranes during demyelination (Figures 7A–D) similar to the findings in the cuprizone model (Figures 3D–F). Tenasin-R was detected in a uniform distribution over the uninjured spinal cord. In the illustrated example of demyelinating injury, identified by clusters of DAPI-stained mononucleated cells, tenasin-R deposits were mainly observed in healthy spinal cord tissue and appeared downregulated from the lesion area at the rim (Figures 7F,G). FAM-CAQK covered the cluster of DAPI+ cells at the lesion rim and accordingly showed no or only

CAQK targets demyelinating regions in the spinal cord in the chronic EAE model

The homing of CAQK peptide in toxin-induced demyelination models prompted further investigations of CAQK targeting under pathophysiological conditions that are closely related to human MS. The chronic mouse EAE model and human MS share several critical features: In both conditions, peripherally activated immune cells infiltrate the brain parenchyma where they cause an amplified immune response that results in tissue damage, demyelination, gliosis and ultimately axon loss. In the widely used EAE model, tissue deficits in the spinal cord correlate with the formation of mononucleated cell clusters and progressive paralysis in experimental animals (Voskuhl et al., 2009; Levy-Barazany and Frenkel, 2012; Hasselmann et al., 2017). We reproducibly induced EAE with an average onset of 7–8 days and peak at 14–15 days by injection of MOG35–55 peptides in groups of 10 or 20 mice (Figure 5A). Focal perivascular lesions in the spinal cords of experimental mice were indicated by clusters of infiltrating DAPI-stained mononucleated cells (Figures 5B–D). CAQK homing was assessed by intravenous injection of FAM-CAQK peptide at disease onset (score 1), peak (score 3–3.5), and at late stages (28 days). FAM-CAQK showed robust targeting to lesion clusters of DAPI+ cells indicating immune cell invasion into the outer rim of the spinal cord parenchyma. In Figure 5, taken from a mouse at peak score, FAM-CAQK peptide targeting is shown in two lesions identified by accumulation of DAPI-stained nuclei in ventral white matter (Figures 5B–D). No peptide is seen in surrounding healthy spinal cord tissue. Similar results were obtained at EAE onset (score 1) and at late stages (28 days post-immunization, data not shown). Control mice injected with PTX only did not develop EAE and did not indicate targeting of FAM-CAQK peptide into the CNS (not shown).
Marginal CAQK peptide association with tenascins in the cuprizone model. Confocal images from the demyelinating corpus callosum of mice on a 6-week cuprizone diet show FAM-CAQK peptide (A,C, green) in complementary distribution with tenasin-R (B, magenta); merged images in (C). FAM-CAQK peptide (D) shows marginal association (white puncta pointed out by arrows in F) with tenasin-C (E magenta). DAPI-staining (blue) indicates cell nuclei in (C,F). D, dorsal; V, ventral; L, lateral; M, medial. Scale bar = 50 µm.

marginal overlap with tenasin-R (Figures 7E–H). Tenasin-C was selectively upregulated in interstitial spaces within DAPI⁺ EAE lesion sites and absent from surrounding healthy CNS tissue (Figures 7K,L). The FAM-CAQK signal overlapped in a fibrous pattern in regions of high tenasin-C accumulation and also covered a large region within the lesion that was devoid of tenasin depositions (Figures 7I–L). Thus, our data provide evidence for FAM-CAQK association with epitopes codistributing with tenasin-C, and simultaneously suggest additional yet unidentified peptide interactions with binding sites exposed on other cellular or extracellular molecules in demyelinating regions.

Discussion

In this study, we report that the four amino acid peptide CAQK selectively targets demyelinating lesions. We show that upon systemic administration and 1 h in circulation, CAQK homes specifically to sites of CNS demyelinating injury and accumulates reliably and reproducibly at sites of myelin damage. We document these homing capacities in three different demyelination models, toxic, chemical, and inflammatory/autoimmune. Both cuprizone and lysolecithin-induced demyelination models are highly reproducible in the time course of demyelination with various degrees of BBB opening and neuroinflammation. CNS access of CAQK peptide through the compromised BBB was previously indicated from studies in the TBI model (Mann et al., 2016) and evident in the focal demyelination lysolecithin model. However, the suggestion that FAM-peptide can reach demyelinating lesions through the nearly closed endothelial barrier is novel. In the cuprizone model at the 6-week timeframe analyzed here, a tight BBB was documented in earlier studies (Bakker and Ludwin, 1987; Kondo et al., 1987; McMahon et al., 2002; Praet et al., 2014). Recent reports re-examining the BBB in the cuprizone model at early and late timepoints also confirmed almost intact barrier functions at the 6-week timepoint. These latter reports indicated compromised BBB permeability at the onset and during the first weeks of cuprizone feeding and progressive repair towards a nearly closed BBB at the 6-week timepoint (Berghoff et al., 2017; Shelestak et al., 2020). How CAQK enters the CNS and how
FIGURE 5

CAQK homes to demyelinating lesions in the mouse model of experimental autoimmune encephalomyelitis (EAE). (A) Disease scores over a 28-day period show EAE progression with an average 7-day onset and a 14-day peak. Control mice show no disease. (B) FAM-CAQK (green) accumulates at lesion sites in the lumbar spinal cords of mice with EAE. Lesions are indicated by clusters of DAPI-stained nuclei (blue) in (C) representing invasions of peripheral inflammatory cells, prominently T-cells and macrophages, into the spinal cord parenchyme. Merged images are shown in (D). Continuous line delimitates the spinal cord tissue. The dotted line indicates area of active EAE lesion. Scale bar: 50 µm.

it interacts with endothelial cells comprising the BBB requires detailed future studies that assess mechanisms in various models and coupled to different tags, therapeutic molecules, or targeting particles. The consistency of peptide targeting to lesion sites in three mouse models of demyelination suggests that CAQK is reliable as a targeting vector for demyelinating lesions in the CNS under diverse states of the BBB.

CAQK targets components of the ECM

The extracellular matrix plays an important role during CNS development, homeostasis, and injury providing cues that regulate cell adhesion, signaling, and motility (Ruoslahti, 1996; Lau et al., 2013; Su et al., 2021). ECM components are secreted by resident cells and assemble into a scaffold in interstitial spaces to regulate a myriad of cellular responses. During white matter injury, the composition of the ECM dynamically changes as hyaluronan is proteolytically fragmented and CSPGs and tenascins are upregulated or remodeled (Lau et al., 2013; de Jong et al., 2020; Srivastava et al., 2020; Diao et al., 2021; Ghorbani and Yong, 2021). The altered ECM is inhibitory to OPC maturation, OPC recruitment to lesion sites, and remyelination (Franklin and Ffrench-Constant, 2008; Czopka et al., 2010).

In this light, it is significant that in the three demyelination models studied here, FAM-CAQK was targeted from the circulation to fibrous extracellular material at lesion sites. Original work from the Ruoslahti laboratory reported CAQK interactions with an extracellular matrix complex composed of versican, hyaluronan, proteoglycan link protein (Hapln), and tenascin-R by affinity purification of injured brain tissue and confirmed peptide colocalization by immunohistochemistry in the TBI model (Mann et al., 2016). Specific CAQK targeted epitopes within the lesioned ECM or its receptors, however, have remained elusive. In the current study, we chose to assess two ECMs, tenascin-R and tenascin-C that are dynamically regulated in white matter lesions and in TBI (George and Geller, 2018). In both the cuprizone and the EAE models at the time points examined, tenascin-R showed lower abundance at lesion sites than in healthy surrounding tissue, and accordingly, no mentionable peptide overlap with tenascin-R was observed. In contrast, tenascin-C
Association of CAQK with invading immune cells and reactive astrocytes at lesions in the EAE model. Fluorescent FAM-CAQK (green in A,D,G,J) homes to lesion sites identified by DAPI+ cell clusters (blue in C,F,I,L) after intravenous application at disease peak. The peptide does not associate with oligodendrocytes (B, magenta) genetically labeled in CNP1-Cre;Rosa26-tdTomato transgenic mice. Merged images in (C). At the gross level, CAQK peptide associates with cells characterizing lesion sites, including reactive astrocytes (GFAP, E, magenta), microglia (Iba1, H, magenta) and infiltrating immune cells (CD3, K, magenta). Merged images are shown in (C,F,I,L), and overlaps indicated in white color are pointed out with yellow arrowheads in (F,I,L). Scale bars: 75 µm.
FIGURE 7
CAQK and tenascins in EAE lesions. (A–D) Confocal images identify FAM-CAQK peptide (A,E,I, green) at DAPI+ lesion clusters (B,F,J, blue) in the lumbar spinal cord of mice with EAE. The peptide does not associate with damaged myelin stained for MBP (C, magenta; merge in D) and largely complements staining for tenasin-R (G, magenta; merge in H). Some overlap is detected between FAM-CAQK and fibrous tenasin-C deposition (K, magenta) as indicated by the white signal in the merged image (L, arrowheads). Note that the majority of the lesion site covered by the peptide is negative for either tenasin (H,L). Scale bars: 20 µm.

deposits appeared to differing degrees within demyelinating lesions in the two models. In the EAE but not in the cuprizone model, CAQK localized to fibrous tenasin-C deposits suggesting that its target sites include epitopes in the local ECM. It is important to note, however, that most of the peptide targeted lesion area was devoid of tenasin-C expression. This leaves open the nature of the peptide interacting molecules at sites of demyelination and studies assessing peptide targeting during the dynamic progression of de- and remyelination will need to provide additional insights.

Our results are mixed regarding the question whether FAM-CAQK peptide homes to specific cellular targets. In none of the current models, the peptide associated with MBP+ demyelinating fibers at lesion sites, and contrary to findings in the TBI model (Mann et al., 2016) oligodendrocytes did not take up the peptide. At gross view, we find populations of reactive astrocytes associated the peptide in all three demyelination models. While our data cannot distinguish the cellular or pericellular distribution of the peptide with reactive astrocytes in the spinal cord models, FAM-CAQK seemed to reside in the cytoplasm of GFAP+ glia in the non-inflammatory cuprizone model (Figure 3). If confirmed, this could suggest autophagic activity during the 1 h in the circulation. In the inflammatory EAE model, CD3+ immune cells and Iba1+ microglia that enter the spinal cord parenchyma to initiate demyelinating lesions sequestered FAM-CAQK peptide from the circulation. Thus, the CAQK peptide associated with cell populations characterizing sites of injury supporting the conclusion that the peptide targets sites of demyelinating injury. Further work will be required to understand the nature of the peptide’s interactions with cells and whether phagocytosis of peptide-associated interstitial components by reactive astrocytic cells and microglia or other parameters are at play.
Potential use of CAQK peptide to achieve remyelination after injury

Remyelination of demyelinated axons restores function and is important for preventing axonal and neuronal degeneration and thus functional and cognitive decline. The findings from the current study raise the possibility for translational purposes in diagnosis and therapeutic applications in aiding myelin repair. Because of its small size, CAQK is a candidate for biomedical imaging, for example for visualizing demyelinating lesions in MRI or PET scans, with CAQK coupled to ultra small super paramagnetic iron oxide nanoparticles (USPIO), or to radioactive tracers, respectively. These technologies are in development for the diagnosis of cancers (Wu et al., 2011; Novy et al., 2019; Ranger and Haubner, 2020), fibrosis (Belkahla et al., 2020), and detection of amyloid plaques in Alzheimer’s models (Wadghiri et al., 2013). Engineering CAQK peptides to adapt to medical imaging might aid earlier diagnosis of white matter lesions and demyelinating diseases.

A highly promising approach, already shown to work in animal models, is to couple the peptide to suitable transport carriers to target and deliver the therapeutic payload. In their original work, Ruoslahti and colleagues provided proof of this principle by targeting siRNA encapsulated in CAQK-coated porous nanoparticles to TBI lesions and locally suppressing gene expression for several days (Mann et al., 2016). Follow-up work in a spinal cord injury model engineered CAQK for exposure on mesenchymal stem cell-derived exosomes to deliver CRISPR/Cas9 plasmids suppressing the pro-inflammatory actions of tumor necrosis factor TNFα. CAQK-mediated targeting the injury site reduced inflammatory TNFα/NFκB signaling pathways, achieved tissue recovery, and restored motor function (Wang et al., 2022). Coupling of CAQK to nanoparticles could similarly enhance the targeting of therapeutic payloads to sites of demyelinating lesions thereby reducing toxicity and off-site effects (Liu et al., 2021). Neutralizing inhibitors of remyelination could enhance OPC recruitment and foster myelin repair, for example by blocking tenascins (Lau et al., 2013; Ghorbani and Yong, 2021; Su et al., 2021), ECM CSPGs (Lau et al., 2012; Keough et al., 2016), Hyaluronan (Back et al., 2005), Lingo-1 (Mi et al., 2008), or components of the Wnt and Notch pathways (John et al., 2002; Williams et al., 2007; Fancy et al., 2009; Syed et al., 2011). Conversely, several drugs including benzotropine, clemastin, quetiapine, clobestasol, and minonazole show effects in improving OPC recruitment and remyelination (Deshmukh et al., 2013; Mei et al., 2014; Najm et al., 2015). Developing CAQK as a vector for targeting and concentrating such drugs at lesion sites may overcome the limits of systemic applications. Systemic drug administration often requires high concentrations and results in undesired side effects, thus packaging therapeutic drugs into peptide-coated natural or artificial particles could increase accumulation at lesion sites and improve myelin repair. Importantly, the CAQK binding epitope is preserved in human injured brain tissue (Mann et al., 2016) which provides an incentive to explore further applications for clinical utilization.

Demyelination is a hallmark of multiple sclerosis and loss of myelin leads to neurodegeneration. White matter abnormalities are evident in multiple neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease and stroke (Chen et al., 2022 for review). With more refined detection methods, maintaining or restoring myelin functions at early stages of the disease may become a promising approach to halt neurodegenerative processes and physical and cognitive decline. By demonstrating CAQK targeting to myelin injuries and sites of progressive demyelination, the work reported here opens new possibilities for potential CAQK applications in early detection and diagnosis of MS and other neurodegenerative disorders and may ultimately prove useful to initiate myelin repair processes to limit neurodegeneration.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was reviewed and approved by Sanford Burnham Prebys Medical Discovery Institute Animal Care and Use Committee (La Jolla, CA). Written informed consent was obtained from the owners for the participation of their animals in this study.

Author contributions

Conceptualization, overall study design, organization of work and manuscript (BR); design and performance of experiments (CA-G: LPC and EAE models; DJ and YK: cuprizone model); manuscript writing or editing (all authors); manuscript revision (BR, CA-G, and DJ). All authors contributed to the article and approved the submitted version.

Funding

This work was supported by a grant from the Office of Extramural Research, National Institute of Health R21 NS098400 to BR (provided salary support for CA-G, supplies and animals for LPC and EAE experiments and a
portion of BR’s salary), R01NS103940 to YK (funded supplies and animals for cuprizone experiments), and TR01 AG71465 to JC (provided support for postdoc DJ).

Acknowledgments

We acknowledge Drs. Erkki Ruoslahti, Aman Mann and Sazid Hussain, SBP, for inspiring and encouraging this work through discussion of their peptide targeting work in the TBI model. We thank Dr. Timothy Huang, SBP, for continued scientific dialogue, Ms. Daniela Grases for pilot experiments and Drs. Dieter Zimmermann and Maria Theresa Dours-Zimmermann, ETH Zürich, for discussion of ECM stainings. A particular thank you goes to Adriana and Buddy Charbono and the SBP Animal Facility for assistance with all animal procedures, to Guillermina Garcia and her team, SBP Histology Facility, for assistance with histological work and to Leslie Boyd, SBP Cell Imaging Facility, for assistance with confocal imaging. Dr. Klaus Nave, MPI Göttingen, Germany, kindly provided the CNP1-Cre mice and Dr. Chris Kintner, Salk Institute, La Jolla, offered valuable comments on the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2022.908401/full#supplementary-material.

References

Arnett, H. A., Fancy, S. P., Albert, J. A., Zhao, C., Plant, S. R., Kaing, S., et al. (2004). bHLH transcription factor Olig is required to repair demyelinated lesions in the CNS. Science 306, 2111–2115. doi: 10.1126/science.1103709

Back, S. A., Tushy, T. M., Chen, H., Wallingford, N., Craig, A., Struve, J., et al. (2005). Hyaluronic acid accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11, 966–972. doi: 10.1038/nm1279

Bakker, D. A., and Ludwin, S. K. (1987). Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases J. Neurol. Sci. 78, 125–137. doi: 10.1016/0022-510X(87)90055-4

Bauch, J., and Faisstner, A. (2022). The extracellular matrix proteins tenascin-C and tenascin-R retard oligodendrocyte precursor maturation and myelin regeneration in a cuprizone-induced long-term demyelination animal model. Cells 11:1773. doi: 10.3390/cells11111773

Bellahla, H., Antunes, J. C., Lalatonne, Y., Sainte Catherine, O., Illoul, C., Journe, C., et al. (2020). USPIO-PiG nanoparticles functionalized with a highly specific collagen-binding peptide: a step towards MRI diagnosis of fibrosis. J. Mater. Chem. B 8, 5515–5528. doi: 10.1039/d0tb00887g

Berghoff, S. A., Duking, T., Spierl, I., WINchenbach, J., Stumpf, S. K., Gerdis, N., et al. (2017). Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model. Acta Neuropathol. Commun. 5:94. doi: 10.1186/s40478-017-0497-6

Bielecki, B., Mattern, C., Ghoumari, A. M., Javaid, S., SMietanka, K., Abi Ghanem, C., et al. (2016). Unexpected central role of the androgen receptor in the spontaneous regeneration of myelin. Proc. Natl. Acad. Sci. U S A 113, 14829–14834. doi: 10.1073/pnas.1614826113

Blaekenore, W. F., and Franklin, R. J. (2008). Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 318, 193–212. doi: 10.1007/978-3-540-73677-6_8

Chen, J. F., Wang, F., Huang, N. X., Xiao, L., and Mei, F. (2022). Oligodendrocytes and myelin: active players in neurodegenerative brains? Dev. Neurobiol. 82, 160–174. doi: 10.1002/dnv2.22867

Colakoglu, G., Bergstrom-Tyberg, U., Berglund, E. O., and Ranscht, B. (2014). Contactin-1 regulates myelination and nodal/paranodal domain organization in the central nervous system. Proc. Natl. Acad. Sci. U S A 111, E394–E403. doi: 10.1073/pnas.1317691110

Constantinescu, C. S., Farooqi, N., O’brien, K., and Gran, B. (2011). Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 164, 1079–1106. doi: 10.1111/j.1476-5381.2011.01302.x

Czopka, T., Von Holst, A., Ffrench-Constant, C., and Faisstner, A. (2010). Regulatory mechanisms that mediate tenascin C-dependent inhibition of oligodendrocyte precursor differentiation. J. Neurosci. 30, 12310–12322. doi: 10.1523/JNEUROSCI.4957-09.2010

Daneman, R., and Prat, A. (2015). The blood-brain barrier. Cold Spring Harr Perspect. Biol. 7:a020412. doi: 10.1101/cshperspect.a020412

de Jong, J. M., Wang, P., Oomkens, M., and Baron, W. (2020). Remodeling of the interstitial extracellular matrix in white matter multiple sclerosis lesions: implications for remyelination (failure). J. Neurosci. Res. 98, 1370–1397. doi: 10.1002/jnr.25482
Pathophysiology of the brain extracellular matrix: a new target for remyelination.

Denic, A., Johnson, A. J., Bieber, A. J., Warrington, A. E., Rodriguez, M., and Pirko, I. (2011). The relevance of animal models in multiple sclerosis research. Pathophysiology 18, 21–29. doi: 10.1016/j.pathophys.2010.04.004

Deshmukh, V. A., Tardif, V., Lysiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., et al. (2013). A regenerative approach to the treatment of multiple sclerosis. Nature 502, 327–332. doi: 10.1038/nature12647

Diao, X., Xiao, M., and Chen, C. (2021). The role of hyaluronan in myelination and remyelination after white matter injury. Brain Res. 1766,147522. doi: 10.1016/j.brainres.2021.147522

El Waly, B., Macchi, M., Cayre, M., and Durbec, P. (2014). Oligodendrogensomes in the normal and pathological central nervous system. Front. Neurosci. 8:145. doi: 10.3389/fnins.2014.00145

Fancy, S. P., Baranzini, S. E., Zhao, C., Yik, D. I., Irvine, K. A., Kaing, S., et al. (2009). Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 23, 1571–1585. doi: 10.1101/gad.1806309

Franklin, R. J. (2002). Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3, 705–714. doi: 10.1038/nrn1917

Franklin, R. J., and Ffrench-Constant, C. (2008). Remyelination in the CNS from biology to therapy. Nat. Rev. Neurol. 9, 839–855. doi: 10.1038/nrneuro0909-839

Franklin, R. J., Ffrench-Constant, C. (2008). Remyelination in the CNS from biology to therapy. Nat. Rev. Neurol. 9, 839–855. doi: 10.1038/nrneuro0909-839

Franklin, R. J., and Goldman, S. A. (2015). Glia disease and repair-remyelination. Cold Spring Harb. Perspect. Biol. 18,753–769. doi: 10.1002 movements. Nat. Rev. Neurosci. 13, 1045–10429. doi: 10.1523/JNEUROSCI.0710-14.2014

Mann, A. P., Scodeller, P., Hussain, S., Ioo, J., Kwon, E., Braun, G. B., et al. (2016). A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. Nat. Commun. 7:11980. doi: 10.1038/ncomms11980

Mapunda, J. A., Tibar, H., Regragui, W., and Engelhardt, B. (2022). How does the immune system enter the brain? Front. Immunol. 13, 805667. doi: 10.3389/fimmu.2022.805667

Marques, S., Pitogrova, E., and Piva, T. J. (2017). Evaluation of the use of therapeutic peptides for cancer treatment. J. Biomed. Sci. 24,1–10. doi: 10.1186/s41598-017-0238-x

Mclachlan, E. J., Suzuki, K., and MatsuMasa, G. K. (2002). Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J. Neuroimmunol. 130, 32–45. doi: 10.1016/j.neuroim.2014.0120111.001

Mei, F., Fancy, S. P. J., Shen, Y. A., Niu, J., Zhao, C., Presley, B., et al. (2014). Microarray arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat. Med. 20, 954–960. doi: 10.1038/nmed.3618

Mi, S., Sandoock, A., and Miller, R. H. (2008). LINGO-1 and its role in CNS repair. J. Biomed. Sci. 15, 2491–2498. doi: 10.1002/jbicol.22928

Mombilovic, M., Stanenkovic, V., Jovanovic, M., Andjus, P. R., Jakovec, I., Schachner, M., et al. (2017). Tenascin-C deficiency protects mice from experimental autoimmune encephalomyelitis. J. Neuroimmunol. 302, 1–6. doi: 10.1016/j.neuroim.2016.12.001

Najm, F. J., Madhavan, M., Zaremba, A., Shick, E., Karl, R. T., Factor, D. C., et al. (2015). Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nat. Med. 22, 216–220. doi: 10.1038/nmed.2014.1335

Novy, Z., Stepankova, J., Hola, M., Lasarova, D., Popper, M., and Petrik, M. (2019). Preclinical evaluation of radiolabeled peptides for PET imaging of glioblastoma multiforme. Mol. Cancer 12,2496. doi: 10.1523/advances.24132496

Olson, E. S., Aguilera, T. A., Jiang, T., Ellies, L. G., Nguyen, Q. T., Wong, E. H., et al. (2009). In vivo characterization of activatable cell penetrating peptides for targeting prostease activity in cancer. Integ. Biol. (Camb) 1,382–393. doi: 10.1039/b904890a

Praet, J., Giallonieltti, C., Berneman, Z., Van Der Linden, A., and Ponsaerts, P. (2014). Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci. Biobehav. Rev. 47, 485–505. doi: 10.1016/j.neubiorev.2014.10.004

Qin, D., Wang, J., Le, A., Wang, T. J., Chen, X., and Wang, J. (2021). Traumatic brain injury: ultrastructural features in neuronal ferroptosis, glial cell activation and polarization and blood-brain barrier breakdown. Cells 10,1009. doi: 10.3390/cells10051009

Rangger, C., and Haubner, R. (2020). Radiolabelled peptides for positron emission tomography and endoradiotherapy in oncology. Pharmaceuticals (Basel) 13,22. doi: 10.3390/ph13020202

Ransohoff, R. M. (2012). Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 15,1074–1077. doi: 10.1038/nneuro.2012.38

Roll, L., and Faisser, A. (2019). Tenascins in CNS lesions. Semin. Cell Dev. Biol. 89,118–124. doi: 10.1016/j.semcdb.2018.09.012

Rauschli, E. (1996). Brain extracellular matrix. Glycobiochem. 6,489–492. doi: 10.1093/hibio/6.5.489

Rauschli, E. (2017). Tumor penetrating peptides for improved drug delivery. Adv. Drug Deliv. Rev. 110,11–12. doi: 10.1016/j.adr.2016.03.008

Rauschli, E., Bhata, S. N., and Sailor, M. J. (2010). Targeting of drugs and nanoparticles to tumors. J. Cell Biochem. 188,759–768. doi: 10.1002/jcb.20910104
Schmidt, T., Awad, H., Slowik, A., Beyer, C., Kipp, M., and Clarner, T. (2013). Regional heterogeneity of cuprizone-induced demyelination: topographical aspects of the midline of the corpus callosum. J. Mol. Neurosci. 49, 80–88. doi: 10.1007/s12031-012-9896-0

Scodeller, P., and Asciutto, E. K. (2020). Targeting tumors using peptides. Molecules 25:808. doi: 10.3390/molecules25040818

Shelestak, J., Singhal, N., Franke, L., Tomor, R., Sternbach, S., Mcdonough, J., et al. (2020). Increased blood-brain barrier hyperpermeability coincides with mast cell activation early under cuprizone administration. PLoS One 15:e0234001. doi: 10.1371/journal.pone.0234001

Skripuletz, T., Guidi, V., Hackstette, D., and Stangel, M. (2011). De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new and the unexpected. Histol. Histopathol. 26, 1585–1597. doi: 10.14670/HH-26.1585

Skripuletz, T., Lindner, M., Kotsiari, A., Garde, N., Fokuhl, J., Linsmeier, F., et al. (2008). Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am. J. Pathol. 172, 1053–1061. doi: 10.2353/ajpath.2008.070850

Srivistava, T., Sherman, L. S., and Back, S. A. (2020). Dysregulation of hyaluronan homeostasis during white matter injury. Neurochem. Res. 45, 672–683. doi: 10.1007/s11064-019-02879-1

Su, M., Soomro, S. H., Jie, J., and Fu, H. (2021). Effects of the extracellular matrix on myelin development and regeneration in the central nervous system. Tissue Cell 69, 101444. doi: 10.1016/j.tice.2020.101444

Syed, Y. A., Hand, E., Mobius, W., Zhao, C., Hofer, M., Nave, K. A., et al. (2011). Inhibition of CNS remyelination by the presence of semaphorin 3A. J. Neurosci. 31, 3719–3728. doi: 10.1523/JNEUROSCI.4930-10.2011

Tagge, I., O’conner, A., Chaudhary, P., Pollar, J., Berlow, Y., Chalupsky, M., et al. (2016). Spatio-temporal patterns of demyelination and remyelination in the cuprizone mouse model. PLoS One 11:e0152480. doi: 10.1371/journal.pone.0152480

Thundimadathil, J. (2012). Cancer treatment using peptides: current therapies and future prospects. J. Amino Acids 2012:967347. doi: 10.1155/2012/967347

Voskhal, R. R., Peterson, R. S., Song, B., Ao, Y., Morales, L. B., Towner-Woodruff, S., et al. (2009). Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J. Neurosci. 29, 11511–11522. doi: 10.1523/JNEUROSCI.1514-09.2009

Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., et al. (2013). Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer’s disease transgenic mice using magnetic resonance microimaging. PLoS One 8:e57097. doi: 10.1371/journal.pone.0057097

Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., et al. (2022). Therapeutic peptides: current applications and future directions. Signal Transduct. Target. Ther. 7:48. doi: 10.1038/s41392-022-00904-4

Williams, A., Piaton, G., Aigrot, M. S., Belhadi, A., Theaudin, M., Petersmann, F., et al. (2007). Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? Brain 130, 2554–2565. doi: 10.1093/brain/awm202

Wu, G., Wang, X., Deng, G., Wu, L., Ju, S., Teng, G., et al. (2011). Novel peptide targeting integrin alphavbeta3-rich tumor cells by magnetic resonance imaging. J. Magn. Reson. Imaging 34, 395–402. doi: 10.1002/jmri.22620

Zhao, C., Fancy, S. P., Franklin, R. J., and Ffrench-Constant, C. (2009). Up-regulation of oligodendrocyte precursor cell alphaV integrin and its extracellular ligands during central nervous system remyelination. J. Neurosci. Res. 87, 3447–3455. doi: 10.1002/jnr.22231

Zimmermann, D. R., and Dours-Zimmermann, M. T. (2008). Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol. 130, 635–653. doi: 10.1007/s00418-008-0485-9